Dynamk Capital

CellFE Biotech is enabling the next generation of cell and gene therapies by efficiently delivering gene-editing payloads with high throughput, and preserving cell function and viability. Envisagenics' mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. Superior technologies and solutions for the production of recombinant proteins in E. Vernal Biosciences provides mRNA and LNP-mRNA manufacturing services to democratize the use of mRNA for all use cases ranging from drug discovery to clinical development across all use cases such as gene editing and regulation, cellular programming, vaccines, mRNA replacement, oncology, autoimmune, and protein degradation. Virica Biotech’s Viral Sensitizer (VSE™) platform reduces production inefficiencies caused by innate anti-viral defenses in manufacturing cells. Customizable solutions substantially increase manufacturing yields and reduce the cost of goods for a range of products, including vaccines, cell and gene therapies, and anti-cancer therapies. Xcell Bioscience’s mission is to enhance the performance and safety of cell and gene-based therapies through the design and development of revolutionary technology platforms. We will keep you up to date on Dynamk Capital news and content.